Literature DB >> 18991338

Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia.

Gil D Rabinovici1, William J Jagust, Ansgar J Furst, Jennifer M Ogar, Caroline A Racine, Elizabeth C Mormino, James P O'Neil, Rayhan A Lal, Nina F Dronkers, Bruce L Miller, Maria Luisa Gorno-Tempini.   

Abstract

OBJECTIVE: Alzheimer's disease (AD) is found at autopsy in up to one third of patients with primary progressive aphasia (PPA), but clinical features that predict AD pathology in PPA are not well defined. We studied the relationships between language presentation, Abeta amyloidosis, and glucose metabolism in three PPA variants using [11C]-Pittsburgh compound B ([11C]PIB) and [18F]-labeled fluorodeoxyglucose positron emission tomography ([18F]FDG-PET).
METHODS: Patients meeting PPA criteria (N = 15) were classified as logopenic aphasia (LPA), progressive nonfluent aphasia (PNFA), or semantic dementia (SD) based on language testing. [11C]PIB distribution volume ratios were calculated using Logan graphical analysis (cerebellar reference). [18F]FDG images were normalized to pons. Partial volume correction was applied.
RESULTS: Elevated cortical PIB (by visual inspection) was more common in LPA (4/4 patients) than in PNFA (1/6) and SD (1/5) (p < 0.02). In PIB-positive PPA, PIB uptake was diffuse and indistinguishable from the pattern in matched AD patients (n = 10). FDG patterns were focal and varied by PPA subtype, with left temporoparietal hypometabolism in LPA, left frontal hypometabolism in PNFA, and left anterior temporal hypometabolism in SD. FDG uptake was significant asymmetric (favoring left hypometabolism) in PPA (p < 0.005) but not in AD.
INTERPRETATION: LPA is associated with Abeta amyloidosis, suggesting that subclassification of PPA based on language features can help predict the likelihood of AD pathology. Language phenotype in PPA is closely related to metabolic changes that are focal and anatomically distinct between subtypes, but not to amyloid deposition patterns that are diffuse and similar to AD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18991338      PMCID: PMC2648510          DOI: 10.1002/ana.21451

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  65 in total

Review 1.  Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria.

Authors:  D Neary; J S Snowden; L Gustafson; U Passant; D Stuss; S Black; M Freedman; A Kertesz; P H Robert; M Albert; K Boone; B L Miller; J Cummings; D F Benson
Journal:  Neurology       Date:  1998-12       Impact factor: 9.910

2.  Enhancement of MR images using registration for signal averaging.

Authors:  C J Holmes; R Hoge; L Collins; R Woods; A W Toga; A C Evans
Journal:  J Comput Assist Tomogr       Date:  1998 Mar-Apr       Impact factor: 1.826

3.  A methodology for specifying PET VOI's using multimodality techniques.

Authors:  G J Klein; X Teng; W J Jagust; J L Eberling; A Acharya; B W Reutter; R H Huesman
Journal:  IEEE Trans Med Imaging       Date:  1997-08       Impact factor: 10.048

4.  Nonfluent progressive aphasia and semantic dementia: a comparative neuropsychological study.

Authors:  J R Hodges; K Patterson
Journal:  J Int Neuropsychol Soc       Date:  1996-11       Impact factor: 2.892

Review 5.  The Neuropsychiatric Inventory: assessing psychopathology in dementia patients.

Authors:  J L Cummings
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

6.  Clinical and pathological evidence for a frontal variant of Alzheimer disease.

Authors:  J K Johnson; E Head; R Kim; A Starr; C W Cotman
Journal:  Arch Neurol       Date:  1999-10

7.  Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory.

Authors:  Randy L Buckner; Abraham Z Snyder; Benjamin J Shannon; Gina LaRossa; Rimmon Sachs; Anthony F Fotenos; Yvette I Sheline; William E Klunk; Chester A Mathis; John C Morris; Mark A Mintun
Journal:  J Neurosci       Date:  2005-08-24       Impact factor: 6.167

8.  In vitro characterization of Pittsburgh compound-B binding to Lewy bodies.

Authors:  Michelle T Fodero-Tavoletti; David P Smith; Catriona A McLean; Paul A Adlard; Kevin J Barnham; Lisa E Foster; Laura Leone; Keyla Perez; Mikhalina Cortés; Janetta G Culvenor; Qiao-Xin Li; Katrina M Laughton; Christopher C Rowe; Colin L Masters; Roberto Cappai; Victor L Villemagne
Journal:  J Neurosci       Date:  2007-09-26       Impact factor: 6.167

9.  Distribution volume ratios without blood sampling from graphical analysis of PET data.

Authors:  J Logan; J S Fowler; N D Volkow; G J Wang; Y S Ding; D L Alexoff
Journal:  J Cereb Blood Flow Metab       Date:  1996-09       Impact factor: 6.200

10.  Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis.

Authors:  S Minoshima; K A Frey; N L Foster; D E Kuhl
Journal:  J Comput Assist Tomogr       Date:  1995 Jul-Aug       Impact factor: 1.826

View more
  213 in total

Review 1.  Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia.

Authors:  William E Klunk
Journal:  Neurobiol Aging       Date:  2011-12       Impact factor: 4.673

2.  The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Guy M McKhann; David S Knopman; Howard Chertkow; Bradley T Hyman; Clifford R Jack; Claudia H Kawas; William E Klunk; Walter J Koroshetz; Jennifer J Manly; Richard Mayeux; Richard C Mohs; John C Morris; Martin N Rossor; Philip Scheltens; Maria C Carrillo; Bill Thies; Sandra Weintraub; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

3.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Clifford R Jack; Marilyn S Albert; David S Knopman; Guy M McKhann; Reisa A Sperling; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

Review 4.  Biomarkers to identify the pathological basis for frontotemporal lobar degeneration.

Authors:  Murray Grossman
Journal:  J Mol Neurosci       Date:  2011-07-22       Impact factor: 3.444

Review 5.  FDG-PET Contributions to the Pathophysiology of Memory Impairment.

Authors:  Shailendra Segobin; Renaud La Joie; Ludivine Ritz; Hélène Beaunieux; Béatrice Desgranges; Gaël Chételat; Anne Lise Pitel; Francis Eustache
Journal:  Neuropsychol Rev       Date:  2015-08-30       Impact factor: 7.444

Review 6.  Towards a clearer definition of logopenic progressive aphasia.

Authors:  Cristian E Leyton; John R Hodges
Journal:  Curr Neurol Neurosci Rep       Date:  2013-11       Impact factor: 5.081

7.  Amyloid imaging in dementias with atypical presentation.

Authors:  David A Wolk; Julie C Price; Charles Madeira; Judy A Saxton; Beth E Snitz; Oscar L Lopez; Chester A Mathis; William E Klunk; Steven T DeKosky
Journal:  Alzheimers Dement       Date:  2012-01-30       Impact factor: 21.566

8.  Extrapyramidal signs in the primary progressive aphasias.

Authors:  Sarah A Kremen; Mario F Mendez; Po-Heng Tsai; Edmond Teng
Journal:  Am J Alzheimers Dis Other Demen       Date:  2011-02       Impact factor: 2.035

9.  Clinical course of primary progressive aphasia: clinical and FDG-PET patterns.

Authors:  Jordi A Matias-Guiu; María Nieves Cabrera-Martín; Teresa Moreno-Ramos; Rocío García-Ramos; Jesús Porta-Etessam; José Luis Carreras; Jorge Matías-Guiu
Journal:  J Neurol       Date:  2014-12-10       Impact factor: 4.849

10.  Quantitative template for subtyping primary progressive aphasia.

Authors:  Marsel Mesulam; Christina Wieneke; Emily Rogalski; Derin Cobia; Cynthia Thompson; Sandra Weintraub
Journal:  Arch Neurol       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.